Inhibition of Complement Activation (Eculizumab) in Guillain-Barre Syndrome Study (ICA-GBS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT02029378

Recruitment Status : Unknown

Verified September 2014 by NHS Greater Glasgow and Clyde.
Recruitment status was: Recruiting

First Posted : January 7, 2014

Last Update Posted : September 23, 2014

Sponsor:

Collaborator:

University of Glasgow

Information provided by (Responsible Party):

NHS Greater Glasgow and Clyde

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Unknown
Estimated Primary Completion Date :	October 2015
Estimated Study Completion Date :	March 2016

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Davidson AI, Halstead SK, Goodfellow JA, Chavada G, Mallik A, Overell J, Lunn MP, McConnachie A, van Doorn P, Willison HJ. Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study. J Peripher Nerv Syst. 2017 Mar;22(1):4-12. doi: 10.1111/jns.12194.

To Top